Winniedel Oncology

About Winniedel Oncology

At Winniedel, we approach clinical trials in oncology with strategy, efficiency, and NO bull. Over 44% of clinical trials are delayed during study start-up. At Winniedel, we have the means to fix this. At the heart of oncology clinical research are the patients who need novel innovations in cancer treatment. Clinical trials can provide them with life-saving therapeutics, even as a drug continues development. Every time there are delays in SSU and FPI, it negatively affects the lives of cancer patients that are waiting on a potential cancer treatment. WINNIEDEL is deeply committed to matching the right sites and the right patients to the right oncology trials, while decreasing SSU and FPI timelines, as well as the failure rate we currently see in cancer drug development. Cancer is a highly personal and scientifically complex condition, and we believe that leveraging personal connection and scientific expertise is the best way to make real, lasting progress in oncology research. Whether advancing early-stage clinical trials or seeking strategic guidance for your medical development pipeline, our experts will connect you to the site and patients your project needs, and ensure your trials are executed with precision, insight, and innovation. As the world’s only CRO focusing exclusively on early-phase oncology study start-ups, our one of a kind approach allows sponsors the ability to save money and time for what matters most...ending cancer. On average, our approach saves sponsors 30%-40% in costs compared to traditional CROs. We act as a gateway to position new developers and researchers with a diverse, global network of cancer centers available and willing to be your study’s following clinical trial site. Our global oncology site universe (GOSU) is at your fingertips; we offer you access to 250+ study sites in 28 countries, a KOL network and agile vendor partners across the globe. WINNIEDEL is a proud member of BioHouston.

View contact profiles from Winniedel Oncology